AAIC July 1 - 2025 Supporting materials Sustained clinically meaningful efficacy and consistent safety in patients with agitation associated with dementia due to Alzheimer’s disease treated with brexpiprazole: a 24-week post hoc analysis Treatment Patterns of Agitation associated with Alzheimer’s Dementia (AAD) Patients in Canada Efficacy of brexpiprazole on caregiver-identified bothersome agitation symptoms that influence the decision to transfer to long-term care: a 24-week post hoc analysis of patients with dementia due to Alzheimer’s disease
